<div id="readability-page-1"><p><span>Akero Therapeutics (NASDAQ:AKRO - Get Free Report)</span> was downgraded by equities research analysts at Canaccord Genuity Group from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Thursday, MarketBeat reports. They currently have a $54.00 price objective on the stock, down from their prior price objective of $73.00. Canaccord Genuity Group's price objective indicates a potential downside of 0.15% from the stock's current price.</p><p>AKRO has been the topic of a number of other reports. TD Cowen started coverage on shares of Akero Therapeutics in a research report on Monday, August 4th. They issued a &#34;buy&#34; rating and a $76.00 price target on the stock. Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They issued a &#34;buy&#34; rating on the stock. Wall Street Zen raised Akero Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 3rd. HC Wainwright started coverage on Akero Therapeutics in a research note on Thursday, September 4th. They issued a &#34;buy&#34; rating and a $72.00 price objective on the stock. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Akero Therapeutics in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $75.63.</p><div><p><span></span><span>Get <strong>Akero Therapeutics</strong> alerts:</span></p></div><p><b>Get Our Latest Analysis on Akero Therapeutics</b></p><h2>Akero Therapeutics Stock Up 16.3%</h2><p>NASDAQ AKRO opened at $54.08 on Thursday. The company has a current ratio of 12.66, a quick ratio of 12.66 and a debt-to-equity ratio of 0.02. The stock's 50 day moving average is $47.04 and its two-hundred day moving average is $46.72. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -27.04 and a beta of -0.29. Akero Therapeutics has a 1-year low of $21.34 and a 1-year high of $58.40. </p><p>Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.11. During the same period last year, the business posted ($0.81) earnings per share.  Equities analysts forecast that  Akero Therapeutics will post -3.99 earnings per share for the current fiscal year. </p><h2>Insider Transactions at Akero Therapeutics</h2><p>In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $43.25, for a total transaction of $1,297,500.00. Following the transaction, the chief executive officer directly owned 475,698 shares in the company, valued at approximately $20,573,938.50. This represents a 5.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Timothy Rolph sold 12,500 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $44.17, for a total transaction of $552,125.00. Following the transaction, the insider owned 167,124 shares in the company, valued at approximately $7,381,867.08. The trade was a 6.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 149,253 shares of company stock worth $6,982,414. 7.07% of the stock is owned by insiders. </p><h2>Hedge Funds Weigh In On Akero Therapeutics</h2><p>Several large investors have recently bought and sold shares of AKRO. FNY Investment Advisers LLC acquired a new position in shares of  Akero Therapeutics in the 2nd quarter valued at $28,000.  Northwest &amp; Ethical Investments L.P. acquired a new position in  Akero Therapeutics in the first quarter valued at about $32,000.  PNC Financial Services Group Inc. lifted its stake in  Akero Therapeutics by 30.8% in the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the period.  TD Waterhouse Canada Inc. acquired a new position in  Akero Therapeutics in the second quarter valued at about $71,000.  Finally, GF Fund Management CO. LTD. raised its position in shares of  Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company's stock valued at $72,000 after acquiring an additional 321 shares during the period. </p><h2>Akero Therapeutics Company Profile</h2> (Get Free Report)<p>Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Akero Therapeutics</li><li>There Are Different Types of Stock To Invest In</li><li>Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>Let the Good Times Roll: 2 Stocks Showing No Signs of Slowing</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s Move</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtSTw"/></p><h2>Should You Invest $1,000 in Akero Therapeutics Right Now?</h2><p>Before you consider Akero Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.</p><p>While Akero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AKRO

<p>Canaccord Genuity Group downgraded Akero Therapeutics (NASDAQ:AKRO) from a "buy" to a "hold" rating, reducing the price target from $73.00 to $54.00. This indicates a potential downside of 0.15% from the current stock price. Despite the downgrade, seven analysts rate the stock as a "buy," with a consensus price target of $75.63. Akero's stock opened at $54.08, showing a 16.3% increase. Recent insider transactions included significant share sales by CEO Andrew Cheng and another insider, reflecting a decrease in their ownership stakes.</p>

Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold